Sleep Disorders is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Sleep Disorders have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Sleep Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sleep Disorders overview

Sleep disorders encompass a range of conditions affecting the quality, timing, and pattern of sleep, leading to difficulties in falling asleep, staying asleep, or experiencing refreshing sleep. These disorders include insomnia, sleep apnea, narcolepsy, restless legs syndrome, and parasomnias like sleepwalking or night terrors. Causes can be multifaceted, involving lifestyle factors, underlying health conditions, medications, or disruptions in the body’s internal clock. Symptoms vary but often involve excessive daytime sleepiness, irritability, difficulty concentrating, or impaired daytime functioning. Diagnosis entails clinical assessments, sleep studies, and medical history reviews. Treatment approaches depend on the specific disorder and may involve lifestyle changes, behavioral therapy, medications, or devices to manage symptoms and improve sleep quality.

For a complete picture of PTSR and LoA scores for drugs in Sleep Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.